Zanubrutinib is a second-generation Bruton’s tyrosine kinase inhibitor (BTKi) designed for selectivity, potency, and bioavailability.
BGB-16673 is an investigational BTK-targeted protein degrader.
Tislelizumab is a humanized IgG4 mAb that binds to PD-1 with high affinity and specificity.
BGB-43395 is an investigational CDK4 inhibitor developed to maximize sustained CDK4 pathway suppression while sparing CDK6
BGB-B2033 is an IgG-based bispecific antibody targeting GPC3 on tumor cells and the costimulatory receptor 4-1BB on T cells.
BG-C9074 is an investigational ADC that targets B7-H4, with an innovative drug-linker design, a DAR of 6 (DAR6), and strong bystander effect
BG-C477 is investigational antibody-drug conjugate (ADC) targeting CEA.
